

Counterfeit Pharmaceuticals & Medical Devices – A Global Regulatory Overview

Dr. Mark R. Willis
US University, USA



Abstract

The threat and proliferation of counterfeit pharmaceuticals has escalated over the last 15 years. In 2016, the World Health Organization estimated that 10 to 30 percent of all pharmaceuticals globally are counterfeit, though this number can increase up to 50 to 70 percent in some underdeveloped and in-transit nations. While WHO estimated that only 10 percent of the pharmaceuticals in the United States (U.S.) market are counterfeit, this was still a considerable amount. According to the IQVIA Institute for Human Data Sciences, in 2016 the United States dispensed a total of 4.453 billion prescription drugs. This quantity is estimated to grow to over five billion by 2021. If 10 percent of those prescriptions dispensed were counterfeit according to WHO's estimates, then nearly 500 million counterfeit prescriptions were consumed throughout the United States in 2016. Consumers are largely unaware of the risk of counterfeit pharmaceuticals. While the global health authorities have focused on implementing laws and policies to mitigate the risk of counterfeit pharmaceuticals seeping onto the market, consumers are left unaware of the danger. As global economies implement laws and regulations to combat the growing epidemic, little has been done to understand the impact on the industry and, ultimately, the consumer. This program will take a broader look at the regulations that have been implemented, how they are impacting the entire drug / device supply chain, and the resulting effect on the consumer.



Speaker Publications:

- 1 “Matching daily healthcare provider capacity to demand in advanced access scheduling systems”; European Journal of Operational Research, Volume 183, Issue 2, 1 December 2007, Pages 812-826
- 2.“ No-shows to primary care appointments: subsequent acute care utilization among diabetic patients”;Springer, 2012, 304 (2012)
- 3.“ Hip arthroscopy versus best conservative care for the treatment of femoroacetabular impingement syndrome (UK FASHIoN): a multicentre randomised controlled trial, The Lancet, Pages 2225-2235, Volume 391, Issue 10136,

[9th International Conference on Pharmaceutical Regulatory Affairs and IPR](#) October 16-17, 2020 Webinar

Abstract Citation:

Dr. Mark R. Willis, “Counterfeit Pharmaceuticals & Medical Devices – A Global Regulatory Overview and the Impact on the Industry”, Regulatory Affairs 2020, 9th International Conference on Pharmaceutical Regulatory Affairs and IPR October 16-17, 2020 Webinar,

<https://regulatoryaffairs.pharmaceuticalconferences.com/speaker/2020/dr-mark-r-willis-us-university-usa>

Biography:

Dr. Willis is a seasoned Pharmaceuticals and Medical Device professional with over 20 years' experience in the industry. With a doctorate in law and public policy, Dr. Willis has supported corporations with their regulatory compliance. As a professor at various US Universities, Mark has been training and mentoring the next generation of professionals for the future regulatory environment. Mark is currently working with global health authority agencies, the UN, and USAID to conduct research to secure the pharmaceutical supply chain. Dr. Willis is also the author of “Counterfeit Pharmaceuticals: Are the U.S. Consumers Aware of the Potential Risks?”